Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Eric Ostertag, insider at Poseida Therapeutics
Eric Ostertag Insider Alerts

Get notified the next time Eric Ostertag buys or sells Poseida Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Eric Ostertag Insider Information

Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our Chief Executive Officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the Chief Executive Officer and President of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as Chief Executive Officer and President of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as Executive Vice President of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. Dr. Ostertag received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison.

What is Eric Ostertag's net worth?

The estimated net worth of Eric Ostertag is at least $3.84 million as of June 1st, 2021. Dr. Ostertag owns 542,985 shares of Poseida Therapeutics stock worth more than $3,838,904 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Ostertag may own. Additionally, Dr. Ostertag receives an annual salary of $858,680.00 as CEO at Poseida Therapeutics. Learn More.

How old is Eric Ostertag?

Dr. Ostertag is currently 48 years old. There are 5 older executives and no younger executives at Poseida Therapeutics. Learn More.

What is Eric Ostertag's salary?

As the CEO of Poseida Therapeutics, Inc., Dr. Ostertag earned a total compensation package of $858,677.00 in 2020. Dr. Ostertag earned a salary of $548,115.00, non-equity compensation of $301,460.00, and other compensation of $9,102.00.

How do I contact Eric Ostertag?

The corporate mailing address for Dr. Ostertag and other Poseida Therapeutics executives is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Poseida Therapeutics can also be reached via phone at 858-779-3100.

Has Eric Ostertag been buying or selling shares of Poseida Therapeutics?

Within the last three months, Eric Ostertag has sold $274,775.00 in Poseida Therapeutics stock. Most recently, Eric Ostertag sold 18,924 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $7.09, for a transaction totalling $134,171.16.

Who are Poseida Therapeutics' active insiders?

Poseida Therapeutics' insider roster includes Kerry Ingalls (COO), Eric Ostertag (CEO), and Matthew Spear (Insider).

Are insiders buying or selling shares of Poseida Therapeutics?

During the last twelve months, Poseida Therapeutics insiders bought shares 7 times. They purchased a total of 172,290 shares worth more than $1,211,059.30. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 436,036 shares worth more than $4,029,562.94. The most recent insider tranaction occured on December, 1st when Director Life Sciences Holdings L Malin bought 18,365 shares worth more than $125,800.25. Insiders at Poseida Therapeutics own 44.0 % of the company.

Information on this page was last updated on 12/1/2021.

Eric Ostertag Insider Trading History at Poseida Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2021Sell18,924$7.09$134,171.16View SEC Filing Icon  
10/1/2021Sell20,029$7.02$140,603.58View SEC Filing Icon  
9/20/2021Sell20,000$8.00$160,000.00View SEC Filing Icon  
9/14/2021Sell20,000$8.14$162,800.00View SEC Filing Icon  
7/1/2021Sell20,563$9.77$200,900.51View SEC Filing Icon  
6/1/2021Sell41,194$8.61$354,680.34542,985View SEC Filing Icon  
5/3/2021Sell18,326$9.01$165,117.26542,985View SEC Filing Icon  
4/5/2021Sell57,819$9.66$558,531.54542,985View SEC Filing Icon  
4/1/2021Sell57,181$9.55$546,078.55542,985View SEC Filing Icon  
2/16/2021Sell133,149$10.00$1,331,490.00431,590View SEC Filing Icon  
2/10/2021Sell12,389$10.00$123,890.00431,590View SEC Filing Icon  
1/21/2021Sell4,462$10.00$44,620.00364,056View SEC Filing Icon  
See Full Table

Eric Ostertag Buying and Selling Activity at Poseida Therapeutics

This chart shows Eric Ostertag's buying and selling at Poseida Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Poseida Therapeutics Company Overview

Poseida Therapeutics logo
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.07
Low: $6.97
High: $7.53

50 Day Range

MA: $6.81
Low: $6.23
High: $7.61

2 Week Range

Now: $7.07
Low: $6.20
High: $13.98

Volume

143,387 shs

Average Volume

252,514 shs

Market Capitalization

$441.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!